Skip Navigation

Massachusetts General Hospital

Location

Massachusetts General Hospital
Hematopoietic Stem Cell Transplant
& Cellular Therapy Program
55 Fruit Street, Yawkey 9E
Boston, MA 02114
Direct phone: (617) 724-1124

Total transplants by cell source

From January 1, 2019 to December 31st, 2020
  • Marrow: 10
  • PBSC: 172
  • Cord Blood: 0
  • Autologous (PBSC or Marrow): 115
Performs adult transplants

Overview

MGH is a FACT accredited program. The Hematopoietic Stem Cell Transplant (HSCT) and Cellular Therapy program offers a comprehensive range of transplant services including myeloablative and reduced intensity matched related and unrelated donor transplants, cord blood transplants and haploidentical donor transplants as well as recent advances in gene modified autologous cellular therapy products such as chimeric antigen receptor T-cells (CAR-T). Our program has state of the art facilities for both inpatient and outpatient care that includes a 32 bed inpatient unit. This center has been performing allogeneic transplants since 1993 and has been an NMDP/Be The Match transplant center since 2007. This center has been performing allogeneic transplants since 1993 and has been an NMDP/Be The Match transplant center since October 2007.

This center has been performing allogeneic transplants since 1993 and has been an NMDP/Be The Match transplant center since October 2007.

Attending physicians

Adult - Yi Bin Chen, Zachariah DeFilipp, Bimal Dey, Areej El-Jawahri, Matthew Frigault, Timothy Graubert, Hanno Hock, Steven McAfee, Paul O'Donnell, Thomas Spitzer

Transplants performed

Marrow/PBSC, single cord, and double cord

Cord blood transplants performed on

Adult only

Other programs and services

For additional information please visit: https://www.massgeneral.org/cancer-center/treatments-and-services/bone-marrow-transplant

About the center

Overview

MGH is a FACT accredited program. The Hematopoietic Stem Cell Transplant (HSCT) and Cellular Therapy program offers a comprehensive range of transplant services including myeloablative and reduced intensity matched related and unrelated donor transplants, cord blood transplants and haploidentical donor transplants as well as recent advances in gene modified autologous cellular therapy products such as chimeric antigen receptor T-cells (CAR-T). Our program has state of the art facilities for both inpatient and outpatient care that includes a 32 bed inpatient unit. This center has been performing allogeneic transplants since 1993 and has been an NMDP/Be The Match transplant center since 2007. This center has been performing allogeneic transplants since 1993 and has been an NMDP/Be The Match transplant center since October 2007.

This center has been performing allogeneic transplants since 1993 and has been an NMDP/Be The Match transplant center since October 2007.

Attending physicians

Adult - Yi Bin Chen, Zachariah DeFilipp, Bimal Dey, Areej El-Jawahri, Matthew Frigault, Timothy Graubert, Hanno Hock, Steven McAfee, Paul O'Donnell, Thomas Spitzer

Transplants performed

Marrow/PBSC, single cord, and double cord

Cord blood transplants performed on

Adult only

Other programs and services

For additional information please visit: https://www.massgeneral.org/cancer-center/treatments-and-services/bone-marrow-transplant

Overall center survival


Patient survival information for this center

This center's actual 1-year survival results are above the expected rate for this center.

The survival information we have for this center includes ONLY:

  1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2017, 2018, 2019, and
  2. Who had their transplant at a U.S. transplant center, and
  3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 267 patients.

The actual 1-year survival of these patients is 79.9%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 69.9% and 79.9%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

Total transplants

Total transplants


297

Transplants reported (From January 1, 2019 to December 31st, 2020 as reported by the centers)

Marrow PBSC Cord blood Total
Allogeneic
Related donor 6 61 0 67
Unrelated donor 4 111 0 115
Total allogeneic 10 172 0 182
Autologous
Both marrow & PBSC
115
-- 115
Total combined
297 0 297

Transplants by disease

All diseases

Number of transplants by age reported from January 1, 2019 to December 31st, 2020 (includes marrow, PBSC and cord blood)

0-18 19-44 45-64 65+ Total
Related 0 21 29 17 67
Unrelated 0 20 41 54 115
Autologous 4 13 57 41 115
Total 4 54 127 112 297

Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.

Centers are not required to report autologous transplants so the numbers might be incomplete.

More information about transplants for this disease can be found:

Additional information

Transplant center resources

Transplant center coordinator:
Adrienne Daigle
(617) 724-6477
Email: adaigle3@partners.org

Financial representative:
Ellen Babine
(617) 724-0009
Email: ebabine@partners.org

Be The Match patient navigators

Patient navigators can answer your questions about choosing a transplant center and provide support and education to help you throughout your transplant journey.

Inside the United States: 1 (888) 999-6743

Outside the United States: 1 (763) 406-3410.
(Long distance or international charges may apply.)

Email: patientinfo@nmdp.org

Survivorship program

Loading survivorship program information...